Korro Bio, Inc.
Company Stats
- Market Cap
- $145.9M
- as of Sep 30, 2026
- Shares Outstanding
- 14.7M
- Free Float
- 33.8%
Income Statement
- Revenue
- $6.4M
- Operating Income
- -$121.9M
- Net Income
- -$117.3M
- EBITDA
- -$117.6M
- Non-cash Impairment
- $30.9M
Cash Flow
- Free Cash Flow
- -$79.1M
- FCF Yield
- -54.2%
- Owner FCF Yield
- -59.4%
Balance Sheet
- Cash & Equivalents
- $21.8M
Returns & Capital
- SBC, 3Y Avg
- $4.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $6.4M | -$79.1M | -1237.2% |
| FY2024 | $2.3M | -$78.0M | -3433.6% |
| FY2023 | $0 | -$75.1M | — |
| FY2022 | $0 | -$58.8M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
XBiotech Leads Buying Intensity; Gold.com Draws $3.93 Million
Stronger demand supports expansion as pricing diverges